OncoMatch/Clinical Trials/NCT06942104
Imaging of Solid Tumors Using 18F-TRX
Is NCT06942104 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies 18F-TRX for solid tumor.
Treatment: 18F-TRX — This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan. It specifically targets and detects labile (unstable) iron levels within tissues, including tumors. Diagnostic procedures, such as 18F-TRX PET/CT or PET/MRI, may help detect tumors in patients with solid tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Prostate Cancer
Renal Cell Carcinoma
Glioblastoma
Disease stage
Required: Stage III, IV, STAGE III RENAL CELL CANCER AJCC V8, STAGE IV RENAL CELL CANCER AJCC V8, STAGE IVB PROSTATE CANCER AJCC V8 (AJCC v8)
Grade: WHO grade 3WHO grade 4 (WHO)
Advanced solid tumor malignancy in one of the following cohorts: ... WHO grade 3 or 4 glioma ... Locally advanced or metastatic clear cell renal cell carcinoma ... Metastatic castration-resistant prostate cancer ... Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Absolute neutrophil count > 1.5 x 10^6/L; Platelets > 75,000 x 10^6/L; Hemoglobin > 8 g/dL
Kidney function
Creatinine clearance > 50 ml/min, calculated using the Cockcroft-Gault equation
Liver function
Total bilirubin < 1.5 x upper limit of normal; AST < 2.5 x ULN (< 5 x ULN with liver metastases); ALT < 2.5 x ULN (< 5 x ULN with liver metastases)
Absolute neutrophil count > 1.5 x 10^6/L; Platelets > 75,000 x 10^6/L; Hemoglobin > 8 g/dL; Total bilirubin < 1.5 x upper limit of normal; AST < 2.5 x ULN (< 5 x ULN with liver metastases); ALT < 2.5 x ULN (< 5 x ULN with liver metastases); Creatinine clearance > 50 ml/min, calculated using the Cockcroft-Gault equation.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06942104 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage III or IV or STAGE III RENAL CELL CANCER AJCC V8 or STAGE IV RENAL CELL CANCER AJCC V8 or STAGE IVB PROSTATE CANCER AJCC V8 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages